Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma<sup>®</sup>) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System
The recent introduction of the innovative therapy, onasemnogene abeparvovec (Zolgensma<sup>®</sup>), has revolutionized the spinal muscular atrophy (SMA) therapeutic landscape. Although Zolgensma<sup>®</sup> therapy has proven to lead to functional improvements in SMA childre...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2024-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|